Recent advances in the use of lipid nanoparticles (LNPs) as delivery vectors for mRNA
Abstract
Therapeutic mRNA has demonstrated great promise in infectious disease vaccines, cancer immunotherapy, and protein replacement therapies. However, its clinical translation is hampered by intrinsic limitations, including rapid degradation, poor membrane permeability, extremely low endosomal escape, lack of tissue specificity, and potential immunogenicity. Naked mRNA alone is insufficient to overcome these challenges, which has driven the emergence of lipid nanoparticles (LNPs) as the leading clinical-grade delivery platform. LNPs employ a four-component system: ionizable lipids for encapsulation and pH-responsive fusion; helper phospholipids and cholesterol for structural integrity and membrane fluidity; and PEGylated lipids for colloidal stability and prolonged circulation. This review systematically addresses LNP composition, structure–activity relationships, and the interplay with extrinsic factors—including administration routes, targeting ligands, immunostimulant co-delivery, and organ tropism (liver, spleen, lungs, lymph nodes)—that collectively govern mRNA biodistribution and therapeutic efficacy. Nonetheless, several major bottlenecks persist, such as unclear endosomal escape mechanisms, PEG-related immune interference, obstacles to extrahepatic delivery, manufacturing complexities, and challenges in AI-driven lipid design. Future progress will rely on integrating rational design, high-throughput screening, and engineering innovations to develop precision delivery systems that are safe, efficient, and amenable to repeated administration—thereby fully unlocking the clinical potential of mRNA-based therapies.